According to a September 8 announcement from the U.S. Food and Drug Administration, the agency has scheduled a public meeting of its Molecular and Clinical Genetics Panel to deliberate and vote on GRAIL's premarket approval application for the Galleri next-generation sequencing methylation-based liquid biopsy. The proceeding marks the first formal advisory committee evaluation of a multi-cancer early detection (MCED) assay designed for presymptomatic screening in individuals aged 50 and older, positioning it as a regulatory inflection point for the entire MCED paradigm. For the molecular diagnostics community, the panel's vote and accompanying rationale will codify the analytical and clinical validation thresholds the FDA expects from future liquid biopsy screening submissions.
Regulatory Architecture
The Galleri assay operates on a bisulfite-conversion NGS workflow that interrogates tumor-derived methylation patterns across the genome, generating a composite cancer signal score and a predicted cancer signal of origin from a single peripheral blood draw. Premarket approval would transition the test from a laboratory-developed procedure under CLIA oversight to an FDA-cleared in vitro diagnostic, introducing conformity requirements spanning manufacturing reproducibility, software lifecycle controls, and post-market performance surveillance. The panel's deliberation is likely to foreground benchmarks specific to screening populations—positive predictive value, interval cancer detection rates, and specificity across benign methylation profiles—where retrospective MCED metrics often diverge from prospective clinical utility.
Operational Implications for Laboratories
Hospital and reference laboratories currently offering Galleri under LDT designation will need to reconcile existing specimen handling, result interpretation, and reflex testing protocols with any PMA-mandated labeling, intended-use parameters, and proficiency testing specifications. The age-50-and-older stratification mirrors GRAIL's pivotal clinical enrollment criteria, though advisory committees routinely probe performance in subgroups underrepresented in registrational data—a scrutiny with direct consequences for how clinical pathology teams document assay performance across diverse patient populations and integrate MCED-positive results into established single-organ screening workflows.
The Broader Liquid Biopsy Landscape
The advisory review arrives amid continued expansion of methylation-based liquid biopsy research, with parallel developments underscoring the methodological convergence on cell-free DNA biomarkers. A separate Bioengineer.org-cited study recently reported a doubling of cancer detection rates in dogs using a blood-based assay, while veterinary and human regulatory pathways remain entirely distinct. The combined trajectory signals an expanding evidentiary base for liquid biopsy screening—one that will increasingly demand harmonized standards for biomarker discovery, analytical validation, and clinical interpretation as the molecular diagnostics enterprise absorbs the next generation of MCED submissions.